Tumor necrosis factor-alpha in isolated perfusion systems in the treatment of cancer: The Rotterdam preclinical-clinical program

Eric R. Manusama; Peet T.G.A. Nooijen; Timo L.M. Ten Hagen; Alex H. Van Der Veen; Mark W.R. De Vries; Johannes H.W. De Wilt; Marc G. Van Ijken; Richard L. Marquet; Alexander M.M. Eggermont

doi:10.1002/(SICI)1098-2388(199804/05)14:3<232::AID-SSU7>3.0.CO;2-9

Tumor necrosis factor-alpha in isolated perfusion systems in the treatment of cancer: The Rotterdam preclinical-clinical program

Eric R. Manusama
, Peet T.G.A. Nooijen
, Timo L.M. Ten Hagen
, Alex H. Van Der Veen
, Mark W.R. De Vries
, Johannes H.W. De Wilt
, Marc G. Van Ijken
, Richard L. Marquet
, Alexander M.M. Eggermont

Research output: Contribution to journal › Review article › peer-review

15 Citations (Scopus)

Abstract

The clinical success of the application of tumor necrosis factor-α (TNFα) in isolated limb perfusions in patients with advanced sarcomas, melanomas and other tumors has renewed the interest in this agent as an anticancer drug. At the Rotterdam Cancer Center, we have developed an interactive preclinical-clinical TNFα program that explores new methods to use TNFα in various settings. Regional organ perfusion models were developed and the effectivity of targeting of TNFα to the tumor by means of systemic administration of liposomes are tested. Furthermore various drugs and mechanisms that may enhance the activity of TNFα ate under investigation. A summary of this comprehensive program is presented here.

Original language	English
Pages (from-to)	232-237
Number of pages	6
Journal	Seminars in Surgical Oncology
Volume	14
Issue number	3
DOIs	https://doi.org/10.1002/(SICI)1098-2388(199804/05)14:3<232::AID-SSU7>3.0.CO;2-9
Publication status	Published - Apr 1998
Externally published	Yes

Keywords

Animal disease models
Extremities
Liposomes
Liver neoplasms
Melanoma
Rats
Regional perfusion
Sarcoma
Tumor necrosis factor

Access to Document

10.1002/(SICI)1098-2388(199804/05)14:3<232::AID-SSU7>3.0.CO;2-9

Cite this

Manusama, E. R., Nooijen, P. T. G. A., Ten Hagen, T. L. M., Van Der Veen, A. H., De Vries, M. W. R., De Wilt, J. H. W., Van Ijken, M. G., Marquet, R. L., & Eggermont, A. M. M. (1998). Tumor necrosis factor-alpha in isolated perfusion systems in the treatment of cancer: The Rotterdam preclinical-clinical program. Seminars in Surgical Oncology, 14(3), 232-237. https://doi.org/10.1002/(SICI)1098-2388(199804/05)14:3<232::AID-SSU7>3.0.CO;2-9

@article{c3e6777df3a94338b401012b0200b642,

title = "Tumor necrosis factor-alpha in isolated perfusion systems in the treatment of cancer: The Rotterdam preclinical-clinical program",

abstract = "The clinical success of the application of tumor necrosis factor-α (TNFα) in isolated limb perfusions in patients with advanced sarcomas, melanomas and other tumors has renewed the interest in this agent as an anticancer drug. At the Rotterdam Cancer Center, we have developed an interactive preclinical-clinical TNFα program that explores new methods to use TNFα in various settings. Regional organ perfusion models were developed and the effectivity of targeting of TNFα to the tumor by means of systemic administration of liposomes are tested. Furthermore various drugs and mechanisms that may enhance the activity of TNFα ate under investigation. A summary of this comprehensive program is presented here.",

keywords = "Animal disease models, Extremities, Liposomes, Liver neoplasms, Melanoma, Rats, Regional perfusion, Sarcoma, Tumor necrosis factor",

author = "Manusama, \{Eric R.\} and Nooijen, \{Peet T.G.A.\} and \{Ten Hagen\}, \{Timo L.M.\} and \{Van Der Veen\}, \{Alex H.\} and \{De Vries\}, \{Mark W.R.\} and \{De Wilt\}, \{Johannes H.W.\} and \{Van Ijken\}, \{Marc G.\} and Marquet, \{Richard L.\} and Eggermont, \{Alexander M.M.\}",

year = "1998",

month = apr,

doi = "10.1002/(SICI)1098-2388(199804/05)14:3<232::AID-SSU7>3.0.CO;2-9",

language = "English",

volume = "14",

pages = "232--237",

journal = "Seminars in Surgical Oncology",

issn = "8756-0437",

publisher = "John Wiley \& Sons Inc.",

number = "3",

}

Manusama, ER, Nooijen, PTGA, Ten Hagen, TLM, Van Der Veen, AH, De Vries, MWR, De Wilt, JHW, Van Ijken, MG, Marquet, RL & Eggermont, AMM 1998, 'Tumor necrosis factor-alpha in isolated perfusion systems in the treatment of cancer: The Rotterdam preclinical-clinical program', Seminars in Surgical Oncology, vol. 14, no. 3, pp. 232-237. https://doi.org/10.1002/(SICI)1098-2388(199804/05)14:3<232::AID-SSU7>3.0.CO;2-9

TY - JOUR

T1 - Tumor necrosis factor-alpha in isolated perfusion systems in the treatment of cancer

T2 - The Rotterdam preclinical-clinical program

AU - Manusama, Eric R.

AU - Nooijen, Peet T.G.A.

AU - Ten Hagen, Timo L.M.

AU - Van Der Veen, Alex H.

AU - De Vries, Mark W.R.

AU - De Wilt, Johannes H.W.

AU - Van Ijken, Marc G.

AU - Marquet, Richard L.

AU - Eggermont, Alexander M.M.

PY - 1998/4

Y1 - 1998/4

N2 - The clinical success of the application of tumor necrosis factor-α (TNFα) in isolated limb perfusions in patients with advanced sarcomas, melanomas and other tumors has renewed the interest in this agent as an anticancer drug. At the Rotterdam Cancer Center, we have developed an interactive preclinical-clinical TNFα program that explores new methods to use TNFα in various settings. Regional organ perfusion models were developed and the effectivity of targeting of TNFα to the tumor by means of systemic administration of liposomes are tested. Furthermore various drugs and mechanisms that may enhance the activity of TNFα ate under investigation. A summary of this comprehensive program is presented here.

AB - The clinical success of the application of tumor necrosis factor-α (TNFα) in isolated limb perfusions in patients with advanced sarcomas, melanomas and other tumors has renewed the interest in this agent as an anticancer drug. At the Rotterdam Cancer Center, we have developed an interactive preclinical-clinical TNFα program that explores new methods to use TNFα in various settings. Regional organ perfusion models were developed and the effectivity of targeting of TNFα to the tumor by means of systemic administration of liposomes are tested. Furthermore various drugs and mechanisms that may enhance the activity of TNFα ate under investigation. A summary of this comprehensive program is presented here.

KW - Animal disease models

KW - Extremities

KW - Liposomes

KW - Liver neoplasms

KW - Melanoma

KW - Rats

KW - Regional perfusion

KW - Sarcoma

KW - Tumor necrosis factor

UR - https://www.scopus.com/pages/publications/0031942952

U2 - 10.1002/(SICI)1098-2388(199804/05)14:3<232::AID-SSU7>3.0.CO;2-9

DO - 10.1002/(SICI)1098-2388(199804/05)14:3<232::AID-SSU7>3.0.CO;2-9

M3 - Review article

C2 - 9548606

AN - SCOPUS:0031942952

SN - 8756-0437

VL - 14

SP - 232

EP - 237

JO - Seminars in Surgical Oncology

JF - Seminars in Surgical Oncology

IS - 3

ER -

Tumor necrosis factor-alpha in isolated perfusion systems in the treatment of cancer: The Rotterdam preclinical-clinical program

Abstract

Keywords

Access to Document

Fingerprint

Cite this